HOME >> BIOLOGY >> NEWS
Blood pressure medication may revolutionize treatment of Marfan syndrome

A commonly prescribed blood pressure medication may provide the first ray of hope in preventing potentially deadly complications of Marfan syndrome, a genetic disease that weakens the structural meshwork of blood vessels. People who have Marfan syndrome have a high risk of developing aortic aneurysm, which can lead to rupture of the heart's largest artery, causing sudden death.

In studies published in the April 7, 2006, issue of the journal Science, Howard Hughes Medical Institute researchers at Johns Hopkins University School of Medicine have shown in mice that the drug losartan, which is manufactured by Merck and sold under the brand name Cozaar, can prevent progression of Marfan syndrome and may also restore normal architecture to the wall of the aorta.

Marfan syndrome is a connective tissue disorder that affects about one in 5,000 individuals. Manifestations include long bone overgrowth, lens dislocation, emphysema, thickening and dysfunction of the heart's mitral valve, and aortic aneurysm with a predisposition for early vascular rupture and sudden death.

Losartan attenuates development of aortic aneurysm by lowering the activity of a pervasive developmental molecule called transforming growth factor beta. In a sea change in thinking about the origins of the disease, researchers have recently discovered that transforming growth factor beta -- not simply a defect in a structural protein -- is most likely responsible for the syndrome's catastrophic developmental defects.

"This is the first therapy for Marfan syndrome that was borne of a systematic effort to elucidate the pathogenesis of the disease," said the senior author of the study, Harry C. Dietz, a Howard Hughes Medical Institute investigator at Johns Hopkins. "I think that this is a rare example where things lived up to the promise that was expressed upon launching the Human Genome Project: If we can identify the genes responsible for a disease, then we will uncover unantici
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
6-Apr-2006


Page: 1 2 3 4 5 6

Related biology news :

1. Blood test may help signal tumors remission, return in throat cancer patients
2. Blood sugars manufacture limited by building blocks supply
3. Bloods clotting cells harbor ticking time bombs, finding may help extend blood supply
4. Blood tests may be possible for mental health conditions
5. Cord Blood Registry achieves industry-leading stem cell recovery with new automation technology
6. Blood test predicts cardiac events and death in heart patients
7. Blood clot fibers more elastic than spiders web
8. Blood-compatible nanoscale materials possible using heparin
9. Blood levels of suspected carcinogen vary by race, ethnicity
10. Blood conservation strategies take center stage at Emory University Hospital forum
11. Blood test for colon cancer risk to be goal of Hopkins project

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... July 16, 2020 , ... ... effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate typical ... that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and ...
(Date:7/2/2020)... (PRWEB) , ... July 01, 2020 , ... ... presented its phase 1a findings of Neihulizumab, a biologic for the treatment of ... June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson ...
(Date:6/28/2020)... ... 25, 2020 , ... In an upcoming episode scheduled for the fall of ... Testing solutions (POCT). Check local listings for more info. , Today, the majority of ... shipped to labs throughout the country. Results are then available several days later. Now, ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... ... diagnostics companies, has announced the placement of Julianne Averill , CPA, as ... leading all financial operations and implementing key business strategies to accelerate Alveo’s growth ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/3/2020)... , ... August 03, 2020 , ... ... today announced Jim Corrigan, President and CEO has been named one of the ... cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how they ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified ... systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , ... one or two switches in a push-pull configuration; yielding fast fall time for ...
Breaking Biology Technology:
Cached News: